Developing a vaccine targeting a key protein in influenza viruses
Official title: Germline targeting for neuraminidase broadly neutralizing antibodies
Funded at Scripps Research Institute, the · NIH-11140166 · Data updated 2026-11-12
This study is working on a new flu vaccine that aims to help your body fight off different strains of the virus by using special antibodies that target a key part of the virus, making it easier for your immune system to recognize and respond to it.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | January 23, 2025 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $230,000 |
| NIH project number | 1R21AI185735-01A1 |
| Project ID | NIH-11140166 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of influenza infection, particularly those with compromised immune systems or underlying health conditions.
✕Less likely to help
Patients who are not at risk for influenza or those who have already been vaccinated with existing vaccines may not benefit from this research.
What this research studies
This research focuses on creating a broad-spectrum influenza vaccine by targeting neuraminidase, a protein that plays a crucial role in the virus's ability to infect cells. The approach involves using broadly neutralizing antibodies (bnAbs) that can bind to a conserved site on neuraminidase, which is typically difficult to access. By employing a technique called germline targeting, the researchers aim to enhance the immune response by priming rare precursor B cells that can develop into these effective antibodies. The study will evaluate promising bnAb candidates and utilize advanced protein engineering methods to design immunogens that can stimulate a robust immune response against various influenza strains.
Why it matters
Potential benefit: If successful, this research could lead to the development of a more effective influenza vaccine that provides broader protection against multiple strains of the virus.
How similar studies have gone: Other research has shown promise in using similar approaches to enhance vaccine efficacy, particularly in targeting conserved viral proteins.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Steichen, Jon — Scripps Research Institute, the
- Study coordinator: Steichen, Jon
Related research
Other NIH-funded projects on the same topics.
-
The Participant Center helps people join and stay in a nationwide health study
A nationwide program to support people in joining, contributing biosamples, and staying connected to a large health study in the United States.
-
Data Sharing and Bioinformatics Core for Viral Systems Biology
A center-led effort to manage, share, and interpret large viral systems biology data using open tools and a community-friendly portal.
-
Germline-targeted HIV vaccines using membrane liposome tech to trigger bnAbs
A new HIV vaccine approach aims to spark broadly neutralizing antibodies by showing MPER on membranes, tested in models and early studies to guide future human trials.
-
Antivirals for hemorrhagic fever viruses like LASV, SFTSV, and EBOV
A multi-institutional effort to find and validate antiviral compounds that block key viral proteins from LASV, SFTSV, and EBOV to help people at risk from serious hemorrhagic fevers.
-
Developing new antivirals for flaviviruses
A research team is working to create oral antiviral drugs targeting flaviviruses to treat infections that affect millions of people.
-
CoV inhibitors targeting non-enzymatic SARS-CoV-2 components
A multicenter research effort seeks antiviral ideas that block SARS-CoV-2 parts that don’t work through traditional enzymes, aiming to help people affected by COVID-19.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.